Omeros confirms submission of response to fda regarding the bla for narsoplimab in the treatment of hsct-tma

Seattle--(business wire)--omeros corporation (nasdaq: omer) today confirmed that earlier this month the company submitted to the u.s. food and drug administration (fda) its response to the agency's complete response letter (crl) for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma). the response comprises a comprehensive briefing package drafted in close collaboration with external clinical, regulatory and legal experts that addr
OMER Ratings Summary
OMER Quant Ranking